Bendamustine

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2069 publications

Response Rate in CLL Patients Treated with Obinutuzumab - Single Centre Experience from University Clinic of Hematology, Skopje.

Response Rate in CLL Patients Treated with Obinutuzumab - Single Centre Experience from University Clinic of Hematology, Skopje.

Journal: Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)
Published: March 21, 2026

High-grade follicular B-cell lymphoma-associated C3 rapidly progressive glomerulonephritis: a rare association.

High-grade follicular B-cell lymphoma-associated C3 rapidly progressive glomerulonephritis: a rare association.

Journal: BMJ case reports
Published: March 16, 2026

Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-543.

Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-543.

Journal: Blood advances
Published: March 13, 2026

Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.

Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.

Journal: The American journal of case reports
Published: March 07, 2026

Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.

Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.

Journal: Leukemia & lymphoma
Published: March 07, 2026

Pure red cell aplasia in a patient with cold agglutinin disease-associated lymphoproliferative disorder

Pure red cell aplasia in a patient with cold agglutinin disease-associated lymphoproliferative disorder

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 04, 2026

Silent imposter in pneumonic attire: primary pulmonary MALT lymphoma.

Silent imposter in pneumonic attire: primary pulmonary MALT lymphoma.

Journal: BMJ case reports
Published: February 06, 2026

Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term study. Blood. 2025;146(suppl 1):1847.

Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term study. Blood. 2025;146(suppl 1):1847.

Journal: Blood
Published: February 05, 2026

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Journal: Cureus
Published: January 29, 2026

A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma.

A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma.

Journal: The Korean journal of internal medicine
Published: January 29, 2026

Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report.

Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report.

Journal: Reports (MDPI)
Published: January 25, 2026

Histopathological Features of Bendamustine Extravasation Injury: A Diagnostic Pitfall in an Immunocompromised Patient.

Histopathological Features of Bendamustine Extravasation Injury: A Diagnostic Pitfall in an Immunocompromised Patient.

Journal: Journal of cutaneous pathology
Published: January 25, 2026
Showing 1-12 of 2,069

Last Updated: 04/28/2026